CAR-T

Also known as: Chimeric Antigen Receptor T-cell therapy

A personalised cell therapy where a patient's T cells are engineered to attack their cancer.

Definition

Chimeric Antigen Receptor T-cell (CAR-T) therapy involves harvesting a patient's T cells, genetically modifying them ex vivo to express a CAR that recognises a tumour antigen (typically CD19, BCMA), expanding them, and re-infusing. Approved CAR-Ts: Kymriah (tisagenlecleucel), Yescarta (axicabtagene), Tecartus, Breyanzi, Abecma, Carvykti. List prices ~$400–500k per dose.

See also

• Mechanism of action — The specific biochemical interaction by which a drug produces its pharmacologic effect.

Other pharmacology terms

• Mechanism of action
• Pharmacokinetics
• Pharmacodynamics
• PROTAC
• ADC
• mAb